Log In
BCIQ
Print this Print this
 

Parcopa, carbidopa/levodopa

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionCarbidopa/levodopa orally disintegrating tablets
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerJazz Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/12/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today